<ѻýҕl>Cases of Breast Implant-Associated Lymphoma Continue to Accumulateѻýҕl> More than 1,300 cases and 35 deaths, as reports of other implant-linked malignancies emerge Mar 06, 2023
<ѻýҕl>Atorvastatin Tied to Cardioprotection for Lymphoma Patients on Anthracyclinesѻýҕl> STOP-CA deemed "an impactful study that will lead to more prescription of statins in patients." Mar 04, 2023
<ѻýҕl>Off-the-Shelf T-Cell Therapy Effective Against Viral Infections After Allo-HCTѻýҕl> Produced an antiviral response in 95% of patients with six different types of infection Jan 13, 2023
<ѻýҕl>Zanubrutinib Shows Good Tolerance in BTK-Inhibitor Intolerant Malignanciesѻýҕl> Most patients had no recurrence of their original intolerance event Jan 10, 2023
<ѻýҕl>Post-HSCT Brentuximab Vedotin Plus Nivolumab Highly Effective in Hodgkin Lymphomaѻýҕl> However, toxic effects might limit the combination to the highest-risk patients Jan 10, 2023
<ѻýҕl>Crystal Ball Cloudy for PI3K Inhibitors' Future in Hematologyѻýҕl> After a year of negative news, some caution about throwing out the baby with the bath water Jan 02, 2023
<ѻýҕl>Anti-PD-1 Drugs Impress as Frontline Therapy for Early, Unfavorable Hodgkin'sѻýҕl> 3-year PFS of 99%, OS of 100% with nivolumab-chemo, high response rate with pembrolizumab Dec 16, 2022
<ѻýҕl>New Regimen for GvHD Prophylaxis in Well-Matched Reduced-Intensity Allo-HCTѻýҕl> Post-transplant cyclophosphamide, tacrolimus, and MMF reduces GvHD without higher relapse risk Dec 14, 2022
<ѻýҕl>'Practice-Changing' Results With Zanubrutinib Versus Ibrutinib in CLL/SLLѻýҕl> Significantly longer PFS with second-gen BTK inhibitor in relapsed/refractory disease Dec 14, 2022
<ѻýҕl>High-Dose Chemo, ASCT Improves Survival in Primary CNS Lymphomaѻýҕl> European trial is "practice-changing as of today," says U.S. expert Dec 13, 2022
<ѻýҕl>Prolonged Responses in DLBCL Spark Talk of a Cure With Bispecific Antibodyѻýҕl> Most complete responses lasted 24 months or longer after limited-duration glofitamab Dec 13, 2022
<ѻýҕl>Pediatric Hodgkin Lymphoma Survivors Experience Accelerated Epigenetic Agingѻýҕl> Data from St. Jude cohort show higher rates of neurocognitive impairment Dec 13, 2022
<ѻýҕl>Ibrutinib Makes Its Case for First-Line Treatment in Mantle Cell Lymphomaѻýҕl> Standard-of-care autologous transplant fails to prove superior to BTK inhibitor alone Dec 11, 2022
<ѻýҕl>Rigid In-Hospital Diet Offers No Advantage in Patients After HSCTѻýҕl> "We should eliminate these silly neutropenic diets," expert says Dec 10, 2022
<ѻýҕl>ADC Offers Promising Results in Relapsed or Refractory Hodgkin Lymphomaѻýҕl> Good response rate with camidanlumab tesirine, although a lot of patients experienced AEs Oct 02, 2022
<ѻýҕl>'Unparalleled Times' in Hematology, but Workforce Issues Persistѻýҕl> "This is the most exciting time ever" to be a hematologist, says ASH President Jane Winter, MD Sep 26, 2022 video
<ѻýҕl>What's on Tap at the Society of Hematologic Oncology's 10th Annual Meetingѻýҕl> Emphasis on novel biological approaches in treating patients with hematologic malignancies Sep 26, 2022
<ѻýҕl>Jane Fonda's Non-Hodgkin Lymphomaѻýҕl> The award-winning actress opened up about her latest health news Sep 06, 2022
<ѻýҕl>What Caused Man's Saddle-Nose Deformity Years After Lymphoma Dx?ѻýҕl> Rare diagnosis points to need for thorough workup in patients with severe nasal congestion Aug 01, 2022
<ѻýҕl>Breast Implant-Related Lymphoma More Common Than Reportedѻýҕl> Contemporary data suggest at least a twofold higher case rate as compared with FDA estimates Jul 21, 2022
<ѻýҕl>Second-Line CAR-T Impresses in Transplant-Ineligible Large B-Cell Lymphomaѻýҕl> More than half of patients achieved complete responses with lisocabtagene maraleucel Jul 18, 2022
<ѻýҕl>Bone Marrow Biopsy Value Limited in Follicular Lymphoma Response Assessmentѻýҕl> Information useful in fewer than 1% of patients with untreated disease Jul 10, 2022
<ѻýҕl>Zanubrutinib Wins in First-Line CLL for Older Patientsѻýҕl> The BTK inhibitor proves superior to bendamustine-rituximab in phase III trial Jul 08, 2022
<ѻýҕl>FDA Warns of Increased Mortality Risk With Duvelisibѻýҕl> Drug approved for adults with CLL/SLL Jul 01, 2022
<ѻýҕl>Brentuximab Vedotin Boosts Survival in Untreated Hodgkin Lymphomaѻýҕl> ECHELON-1 analysis showed 41% mortality risk reduction versus standard treatment Jun 21, 2022
<ѻýҕl>Third-Line BTK Inhibitor Combo Doubles PFS in Follicular Lymphomaѻýҕl> Significantly more responses, CRs with zanubrutinib-obinutuzumab versus anti-CD20 drug alone Jun 05, 2022
<ѻýҕl>Brentuximab Vedotin-Chemo Boosts EFS in High-Risk Pediatric Hodgkin Lymphomaѻýҕl> Combo regimen offers "a new standard for front-line therapy," researcher says Jun 04, 2022
<ѻýҕl>Add-On Ibrutinib Boosts PFS in Untreated, Older Mantle-Cell Lymphoma Patientsѻýҕl> BTK inhibitor plus chemoimmunotherapy increased progression-free survival by over 2 years Jun 03, 2022
<ѻýҕl>FDA Pulls Lymphoma Approvals for PI3K Inhibitor Umbralisibѻýҕl> Worse overall survival observed despite improvements in progression-free survival Jun 01, 2022
<ѻýҕl>Allo-Transplant With Omidubicel Hints at Longer-Term Benefits Tooѻýҕl> "Viable" option for patients eligible for umbilical cord blood transplantation, investigator says Apr 27, 2022
<ѻýҕl>Promising Data for Allo-Transplant After CAR T-Cell Failure in LBCLѻýҕl> Durable responses with no unexpected or prolonged safety issues Apr 27, 2022
<ѻýҕl>Bispecific Antibody-NK Cell Complex Impresses in Early Hodgkin/NHL Trialѻýҕl> Objective responses in 89% of patients with no CRS, neurotoxicity, or graft-versus-host disease Apr 11, 2022
<ѻýҕl>9/11 Responders More Likely to Carry Genetic Mutations Tied to Cancerѻýҕl> Clonal hematopoiesis seen in 10% of firefighters, medical personnel on the scene after WTC attack Mar 07, 2022
<ѻýҕl>FDA Concerned About Safety of Lymphoma Drugѻýҕl> Hint of excess mortality in trial of umbralisib/ublituximab prompts public notice Feb 03, 2022
<ѻýҕl>Growing Controversy Over 'Skinny' Labeling for Generic Drugsѻýҕl> What's at stake in legal battles over patent-avoiding approval pathway for generics Jan 17, 2022
<ѻýҕl>Less Is More: Rituximab Retreatment Tops Maintenance for Follicular Lymphomaѻýҕl> Updated analysis confirms advantages of less aggressive approach to low-burden disease Dec 16, 2021
<ѻýҕl>CAR T-Cell Win Streak Stopped by Negative Trial in Aggressive LBCLѻýҕl> Patients, trial design, logistics among possible explanations for lack of EFS benefit Dec 14, 2021
<ѻýҕl>R-CHOP Toppled in First-Line DLBCL Trialѻýҕl> Replacing vincristine with polatuzumab vedotin improved PFS, without adding toxicity Dec 14, 2021
<ѻýҕl>R2 Maintenance for Elderly MCL Patients Worth the Risk?ѻýҕl> Longer PFS with addition of lenalidomide to rituximab, but also more toxicity Dec 13, 2021
<ѻýҕl>Novel Bispecific Antibody Nets Durable Remissions in Follicular Lymphomaѻýҕl> Mosunetuzumab offers "clinically meaningful outcomes" in relapsed/refractory disease Dec 12, 2021